No abstract

No abstract

diagnostic scenarios resulted in more QALYs and fewer total costs compared to a standard test (dominant ICERs). The greatest benefit was among adults 18-64 using the smartphone-enhanced test at a pharmacy during the off-season for flu (INMB = $124 per person). Most QALY gains were by avoiding treatment side effects in people with non-flu illnesses. Patients benefitted by avoiding productivity loss and payers were predicted to avoid costs of unnecessary drugs and side effects. ConClusions: This economic decision model of a smartphone-enhanced influenza diagnostic projects that the new product could in result cost savings, health gains, and greatest value for patients aged 18-64 when administered in a pharmacy or at home during the off-season for flu.

No abstract